Low doses of dexamethasone constantly delivered by autologous erythrocytes slow the progression of lung disease in cystic fibrosis patients.
暂无分享,去创建一个
Gianluca Damonte | Simona Panunzi | Bruno Dallapiccola | Sergio Bella | Mauro Magnani | G. Damonte | B. Dallapiccola | G. Novelli | M. Magnani | S. Bella | S. Panunzi | L. Rossi | S. Serafini | M. Castro | Giuseppe Novelli | Luigia Rossi | Massimo Castro | Francesco D'Orio | Sonja Serafini | Leonardo Bigi | Ivo Panzani | Pierluigi Di Carlo | I. Panzani | L. Bigi | F. D'Orio | P. Di Carlo
[1] P. Greally,et al. Corticosteroid treatment in cystic fibrosis. , 1993, Archives of disease in childhood.
[2] M. Magnani,et al. Red Blood Cells as a Glucocorticoids Delivery System , 1997 .
[3] Melvin Berger,et al. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology , 1997, Pediatric pulmonology.
[4] T. Miyata,et al. Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. , 1996, The American journal of physiology.
[5] L Bigi,et al. Erythrocyte‐mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease , 2001, Biotechnology and applied biochemistry.
[6] D. Ashby,et al. Oral steroids for cystic fibrosis. , 1999, The Cochrane database of systematic reviews.
[7] D. Schidlow,et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. , 1995, The Journal of pediatrics.
[8] A. De Flora,et al. Heterodimer-loaded erythrocytes as bioreactors for slow delivery of the antiviral drug azidothymidine and the antimycobacterial drug ethambutol. , 1999, AIDS research and human retroviruses.
[9] J. Zieleński. Genotype and Phenotype in Cystic Fibrosis , 2000, Respiration.
[10] J. L. Way,et al. Erythrocytes as Drug Carriers in Medicine , 1997, Springer US.
[11] K. Meert,et al. Dexamethasone for the prevention of postextubation airway obstruction: A prospective, randomized, double-blind, placebo-controlled trial| , 1996 .
[12] G. Novelli,et al. Towards the pharmacogenomics of cystic fibrosis. , 2002, Pharmacogenomics.
[13] C. Nicolau,et al. Improved Oxygen Delivery to Tissues and Iron Chelator Transport through the Use of Lysed and Resealed Red Blood Cells: A New Perspective on Cooley's Anemia Therapy a , 1985, Annals of the New York Academy of Sciences.
[14] B. Rosenstein,et al. Risks of alternate-day prednisone in patients with cystic fibrosis. , 1991, Pediatrics.
[15] R. Schleimer. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. , 1990, The American review of respiratory disease.
[16] G. Damonte,et al. Red Blood Cells as a Delivery System for AZT , 1995 .
[17] A. Zanella,et al. Erythrocyte engineering for drug delivery and targeting , 1998, Biotechnology and applied biochemistry.
[18] R H Glew,et al. Enzyme loading of erythrocytes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[19] E. Zocchi,et al. Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.